在西斯普拉丁治疗后,丸瘤细胞的强烈亡反应
Beate Köberle1,2, Svetlana Usanova3, Andrea Piee-Staffa3
1Institute of Toxicology, University of Mainz Medical Center, 55131, Mainz, Germany. beate.koeberle@kit.edu.
International urology and nephrology
|October 27, 2023
概括
丸生殖细胞瘤 (TGCT) 由于通过死亡受体和线粒体通路的增强亡,以及有限的DNA修复,显示出独特的思丁敏感性. 这就解释了他们使用基化疗的高治愈率.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 大多数固体转移性癌症抵抗化疗,但转移性丸生殖细胞瘤 (TGCT) 显示高治愈率 (>80%) 与西斯治疗.
- TGCT敏感性与有限的DNA修复和亡倾向有关.
研究的目的:
- 调查在对西斯普拉丁敏感的丸瘤细胞 (TTC) 与抗性膀癌细胞中的西斯普拉丁诱导的亡途径激活.
- 阐明TGCT独特的化学敏感性背后的分子机制.
主要方法:
- 流细胞计,酶激活和PARP-1裂变测试用于评估亡.
- 免疫阻塞和RT-PCR用于分析亲和抗亡蛋白 (p53,Bax,Noxa,Bcl-2,Fas/FasL).
- 通过siRNA介导的p53和FAS的淘汰,以准亡信号传递.
主要成果:
- 在TTC中,西斯普拉丁诱导了p53,Bax和Noxa,与Bax转位和细胞染色体C释放.
- Bcl-2只存在于抵抗性膀癌细胞中.
- 在所有细胞系中增加了FasR mRNA和FasL蛋白;p53和FAS敲击减少了细胞亡,并增加了TTC中的 Cisplatin 耐药性.
结论:
- 西斯普拉丁激活TGCT细胞中的死亡受体 (Fas/FasL) 和线粒体亡途径.
- 减弱的DNA修复与强大的亡相结合,解释了TGCT对基药物的异常敏感性.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
2.7K
相关概念视频
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.